N
NGeneBio
NGS-based precision oncology diagnostics and analysis software.
About NGeneBio
NGeneBio is a South Korean molecular diagnostics company specializing in precision oncology. The firm develops and markets Next-Generation Sequencing (NGS)-based diagnostic panels and clinical analysis software for cancer and hereditary diseases.
The company's origins trace back to an in-house venture at Korea Telecom (KT) that developed a large-scale genomic analysis platform in 2012. NGeneBio was officially established in October 2015 as a joint venture between the telecommunications giant KT and cancer diagnostics firm Genecurix. This strategic partnership combined KT's expertise in AI, cloud, and big data with Genecurix's capabilities in cancer diagnostics. The company went public with an initial public offering on December 10, 2020.
Under the leadership of CEO Daechul Choi, NGeneBio aims to advance personalized medicine through its integrated diagnostic solutions. The company's business model centers on the sale of these IVD products to medical institutions and clinical laboratories, which use them for applications in molecular diagnostics (MDx) and companion diagnostics (CDx). Its product line includes panels for hereditary breast/ovarian cancer (BRCAaccuTest™), solid tumors (SOLIDaccuTest™), and hematologic cancers (HEMEaccuTest™). A key offering is the NGeneAnalySys™ software, a platform that provides a comprehensive bioinformatics pipeline for analyzing genomic data, interpreting variants, and generating clinical reports to guide treatment decisions.
NGeneBio achieved a significant milestone by receiving Korea's first approval from the Ministry of Food and Drug Safety (MFDS) and Asia's first CE-IVD mark for its BRCAaccuTest™ genomic diagnostic product. The company is expanding its global footprint through partnerships, such as a collaboration with MGI to pair its diagnostic assays with MGI's DNBSEQ™ sequencing platforms. While NGeneBio has reported significant revenue growth, it has also incurred net losses and recently conducted rights offerings to bolster its financial position and repay debt.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Nov 2018 | $10M | $40M | Korea Venture Investment Corporation · DSC Investment · UTC Investment · IMM Investment | ↗ |
Growth signals
Latest recorded traffic for NGeneBio is 2.9K monthly website visits, down 32.6% over the last three months. NGeneBio's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Korea Venture Investment Corporation
DSC Investment
UTC Investment
IMM Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NGeneBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NGeneBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.